Market Overview:
Huntington’s disease is a genetic disorder that causes the death of brain cells. The main treatment goals are managing the symptoms of Huntington’s disease and improving a patient’s quality of life. Medications, lifestyle adaptations, and therapies are used to treat motor control problems, cognitive decline, and emotional/ behavioral issues.
The global Huntington’s Disease Treatment Market is estimated to be valued at US$ 0.47 Bn in 2023 and is expected to exhibit a CAGR of 20% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The key trend in the Huntington’s disease treatment market involves using gene silencing techniques. Researchers are developing RNA interference (RNAi) therapeutics that can turn off the HTT gene and reduce the production of mutant huntingtin protein. Several companies are conducting clinical trials of potential huntingtin-lowering therapies delivered directly to the brain using special infusion techniques. This gene therapy approach holds promise as a disease-modifying treatment that could slow or stop the progression of Huntington’s disease.
SWOT Analysis
Strength: The increasing prevalence of Huntington’s disease with rising awareness about early diagnosis and treatment options present a strong patient pool for drug developers and pharmaceutical companies. Further, launch of newer disease modifying drugs provide improved treatment outcomes.
Weakness: High treatment costs associated with advanced gene therapies and lack of cure impede greater treatment penetration. Further, challenges in early diagnosis also present a threat.
Opportunity: Emerging pipeline of drugs targeting various disease pathways offer significant growth opportunities. Further, focus on improving accessibility in developing countries present an avenue to tap new patient populations.
Threats: Stringent regulatory pathways for approval of drugs pose delays limiting faster market access. Further, safety issues posed by some emerging therapies remain a challenge limiting broader adoption.
Key Takeaways
The Global Huntington’s Disease Treatment Market Size is expected to witness high growth, exhibiting CAGR of 20% over the forecast period, due to increasing prevalence of Huntington’s disease worldwide. As per estimates, around 12 people per 100,000 populations globally are affected by Huntington’s disease resulting in rising demand for effective treatment and management options.
Regional analysis
North America is expected to dominate the global Huntington’s disease treatment market during the forecast period. This is attributed to higher acceptance of novel therapies, presence of favorable reimbursement policies, increasing awareness about disease treatment, rising healthcare expenditure etc. in the region. Europe is also expected to witness significant growth owing to growing patient population and recent approval of promising drugs in the EU5 markets.
Key players operating in the Huntington’s disease treatment market are Teva Pharmaceutical Industries Ltd (Israel), Amneal Pharmaceuticals LLC. (U.S.), Elekta AB (Sweden), Alnylam Pharmaceuticals, Inc(U.S.), Apotex Inc (Canada), Armata Pharmaceuticals, Inc.(U.S.), Pfizer Inc (U.S.), H. Lundbeck A/S (Denmark), Alterity Therapeutics (Australia)., Vertex Pharmaceuticals Incorporated (U.S.), SK Plc. (U.K.), Ceregene, Inc (U.S.). SOM BIOTECH (Spain), Palobiofarma (Spain), and Ipsen Pharma (France).
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.